论文部分内容阅读
As an endogenous insulinotropic hormone,Glucagon-like peptide-1(GLP-1)has tremendous potential in treating type Ⅱ diabetes.However,it will be rapidly inactivated by dipeptidyl peptidase Ⅳ(DPP-Ⅳ)at the N-terminus in vivo[1],which limits its clinical application in treatment of diabetes.